The monoclonal antibodies market size is estimated to be USD 189,432 million in 2022 and is expected to witness a CAGR of 11.42% during the forecast period 2023-2033. Increasing incidence of chronic diseases such as cancer, cardiovascular disorders, and others, rising mAb therapy applications for targeted therapies and growing patient and physician knowledge of such therapies are factors contributing to the market growth. Additionally, strategic initiatives performed by top companies for the development of mAb products and wide product launches and robust R&D for new product development is expected to propel the market growth. However, rising costs of mAb development and shortage of skilled workforce is expected to hinder the growth.

Strategic initiatives performed by top companies for the development of mAb products is expected to drive the market. For instance, Atlas Antibodies AB and T-Cure Bioscience, Inc. collaborated together to produce and supply CT83 mAbs in October 2021. Similar to this, Ono Pharmaceutical Co., Ltd. and Neurimmune AG partnered up to develop mAb medicines against new therapeutic targets for neurodegenerative diseases in January 2022.

Wide product launches and robust R&D for new product development is predicted to fuel the market growth. The potential for the monoclonal antibodies market to grow will be spurred by a strong emphasis on the research and development of novel monoclonal antibody therapeutics to provide highly targeted treatment for complex and severe diseases. Industry participants will substantially benefit from government assistance and regulatory permits for the expansion of the monoclonal antibody business. For instance, the European Commission (EC) authorised Bristol Myers Squibb’s OPDIVO and Yervoy combination therapy in June 2021 to treat patients with malignant pleural mesothelioma.

Segmentation

By Source Type

The market is categorized into chimeric, human, murine and humanized. In the global market, the human segment accounted for the largest revenue share in 2022 owing to the fact that human mAbs are less immunogenic than chimeric or humanised mAbs and offer effective function regulation. The development of completely human mAbs is therefore projected to grow in the near future as a result of recent technological advancements in genetic engineering. Humanized mAbs are anticipated to exhibit the fastest CAGR throughout the projection period due to their widespread application against a variety of target antigens such as cancer cells, immunosuppression, and immunomodulatory molecules.

By Production Type

The market is divided into in vitro and in vivo. In 2022, the in vitro accounted for the highest revenue share due to its financial stability over lengthy production runs and lesser susceptibility for contamination with foreign antigens. In vivo type is anticipated to expand at a significant rate throughout the projected period due to its improved cost-effectiveness compared to in vitro techniques and capacity to generate mAbs in high concentrations. These mAbs are applied in the diagnostic sector, where cost-saving measures are crucial, and mAb secretion can be increased by optimising in vivo methods.

By Application

The market is segregated into autoimmune diseases, oncology, neurological diseases, infectious diseases, and others. In the global market, the oncology segment accounted for the largest revenue share in 2022 owing to large number of regulatory approvals for mAbs used in the treatment of cancer. One major driver that is expected to fuel the growth of mAb therapies is the rise in cancer incidence, as these pharmaceuticals can have fewer side effects than other medications and chemotherapy treatments. Applications of mAbs for the treatment of these conditions are anticipated to expand at a fast rate due to the rising incidence of autoimmune diseases including rheumatoid arthritis. Furthermore, it is predicted that applications of mAbs in this field will expand as more cytokine proteins that can be targeted for disease mitigation are discovered in inflammatory pathways.

By End Use

The market is segmented into specialty centres, hospitals, and others. In 2022, the hospitals segment accounted for the largest revenue share owing to growing usage of mAbs for cancer treatment at hospitals. The specialty centres held a large market share due to growing government funding in recent years. For instance, the National Cancer Institute’s Cancer Centers Program, which focuses on the prevention, detection, and treatment of various cancers, is developing guidelines for transdisciplinary cancer centres. These activities are anticipated to have a favourable impact on segment growth.

Regional Markets

In 2022, North America region accounted for the highest revenue in the monoclonal antibodies market and is expected to maintain its dominance during the forecast period. This is attributed to its extensive healthcare infrastructure, high patient awareness, and expanding opportunities for cancer research. In addition, rising government funding for cancer research and the presence of major companies like Pfizer Inc., Amgen Inc., and Merck & Co., among others, are predicted to spur market expansion. The Asia Pacific region is predicted to develop at the quickest rate during the projection period due to rising disposable income, a huge patient pool for mAb cancer therapies, and a growing emphasis on healthcare. Clinical research funding opportunities are appealing in nations like China and India, which is expected to improve the chances for mAb research and development.

Competitor Insights

Some of the key players operating in the monoclonal antibodies market are GlaxoSmithKline plc, Merck & Co., Inc., Abbott Laboratories, Biogen Inc., AstraZeneca plc, Eli Lilly And Company, Novartis AG, Johnson & Johnson Services, Inc., Bayer AG, Amgen Inc., Bristol Myers Squibb, F. Hoffman-La Roche Ltd., Viatris Inc., Pfizer Inc, Daiichi Sankyo Company, Limited, Thermo Fisher Scientific, Inc., Novo Nordisk A/S, Sanofi S.A., and Merck KGaA.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, Sanofi S.A. and Blackstone Life Sciences collaborated to develop a subcutaneous Sarclisa mAb formulation faster for the treatment of multiple myeloma patients in March 2022.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including source type, production type, application, and end use from 2023 to 2033

Report Scope:

Segmentation: Monoclonal Antibodies Market Report 2022 – 2033

Source (Revenue, USD Million), 2022 – 2033

• Chimeric
• Human
• Murine
• Humanized

Production Type (Revenue, USD Million), 2022 – 2033

• In Vitro
• In Vivo

Application (Revenue, USD Million), 2022 – 2033

• Autoimmune Diseases
• Oncology
• Neurological Diseases
• Infectious Diseases
• Others

End Use (Revenue, USD Million), 2022 – 2033

• Specialty Centres
• Hospitals
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA